Lyra Total Assets vs Asset Turnover Analysis
| LYRA Stock | USD 0.21 0.02 10.53% |
Lyra Therapeutics financial indicator trend analysis is infinitely more than just investigating Lyra Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lyra Therapeutics is a good investment. Please check the relationship between Lyra Therapeutics Total Assets and its Asset Turnover accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.
Total Assets vs Asset Turnover
Total Assets vs Asset Turnover Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lyra Therapeutics Total Assets account and Asset Turnover. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Lyra Therapeutics' Total Assets and Asset Turnover is -0.66. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Asset Turnover in the same time period over historical financial statements of Lyra Therapeutics, assuming nothing else is changed. The correlation between historical values of Lyra Therapeutics' Total Assets and Asset Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Lyra Therapeutics are associated (or correlated) with its Asset Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Asset Turnover has no effect on the direction of Total Assets i.e., Lyra Therapeutics' Total Assets and Asset Turnover go up and down completely randomly.
Correlation Coefficient | -0.66 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Total Assets
Total assets refers to the total amount of Lyra Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lyra Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Asset Turnover
The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.Most indicators from Lyra Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lyra Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.At present, Lyra Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 73.5 M, whereas Selling General Administrative is forecasted to decline to about 12.6 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 102K | 1.0M | 4.1M | 4.3M | Net Interest Income | 102K | 1.0M | 4.1M | 4.3M |
Lyra Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Lyra Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lyra Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 15.0M | 80.8M | 54.9M | 110.0M | 142.6M | 78.6M | |
| Other Current Liab | 110K | 2.0M | 3.2M | 9.0M | 3.9M | 3.6M | |
| Total Current Liabilities | 5.2M | 4.9M | 18.2M | 14.5M | 19.6M | 11.8M | |
| Total Stockholder Equity | 7.3M | 74.5M | 34.3M | 80.8M | 89.4M | 93.9M | |
| Net Tangible Assets | (123.3M) | 74.5M | 34.3M | 80.8M | 92.9M | 97.5M | |
| Net Debt | (6.5M) | (72.2M) | (44.3M) | (30.3M) | 4.5M | 4.8M | |
| Retained Earnings | (127.8M) | (149.9M) | (193.4M) | (248.7M) | (311.4M) | (295.8M) | |
| Accounts Payable | 1.1M | 922K | 3.1M | 2.6M | 3.1M | 2.1M | |
| Cash | 9.8M | 74.6M | 45.7M | 32.6M | 22.4M | 38.3M | |
| Non Current Assets Total | 4.8M | 4.9M | 6.9M | 9.1M | 37.8M | 39.7M | |
| Non Currrent Assets Other | 1.1M | 118K | 762K | 3.3M | 2.5M | 1.5M | |
| Other Assets | 1.4M | 2.7M | 1.1M | 4.7M | 5.4M | 5.6M | |
| Cash And Short Term Investments | 9.8M | 74.6M | 45.7M | 97.9M | 102.8M | 65.0M | |
| Common Stock Shares Outstanding | 12.9M | 8.6M | 13.0M | 30.2M | 49.8M | 52.3M | |
| Liabilities And Stockholders Equity | 15.0M | 80.8M | 54.9M | 110.0M | 142.6M | 78.6M | |
| Non Current Liabilities Total | 2.4M | 1.5M | 2.3M | 14.7M | 33.6M | 24.7M | |
| Capital Lease Obligations | 3.3M | 2.4M | 1.5M | 2.2M | 26.9M | 28.2M | |
| Other Current Assets | 311K | 2.6M | 4.3M | 2.9M | 2.1M | 2.4M | |
| Other Stockholder Equity | 4.4M | 305.2M | 227.7M | 329.4M | 400.7M | 209.8M | |
| Total Liab | 7.6M | 6.3M | 20.6M | 29.2M | 53.2M | 33.2M | |
| Net Invested Capital | 7.3M | 74.5M | 34.3M | 80.8M | 89.4M | 93.9M | |
| Total Current Assets | 10.1M | 75.9M | 47.9M | 100.8M | 104.8M | 66.8M | |
| Net Working Capital | 4.9M | 71.0M | 29.7M | 86.4M | 85.2M | 55.0M | |
| Property Plant Equipment | 3.4M | 2.2M | 5.9M | 4.5M | 5.1M | 3.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lyra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lyra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lyra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lyra Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.023 | Quarterly Revenue Growth (0.64) | Return On Assets (0.42) | Return On Equity (1.86) |
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.